Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Qiagen ( (QGEN) ) is now available.
Qiagen N.V. announced a significant transaction involving the sale of shares by Mr. Roland Sackers, a member of the managing body. The shares, sold between August 13 and 15, 2025, on the NYSE, represented approximately 15% of his overall holdings, amounting to a total transaction value of $1,546,258.43. This transaction could indicate a strategic financial decision by the management, potentially impacting stakeholders’ perception of the company’s future performance.
The most recent analyst rating on (QGEN) stock is a Hold with a $42.50 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V. is a company operating in the biotechnology industry, specializing in the development and sale of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its focus on providing solutions for the extraction and analysis of DNA, RNA, and proteins, and it is listed on multiple stock exchanges including NYSE and various European markets.
Average Trading Volume: 1,463,714
Technical Sentiment Signal: Buy
Current Market Cap: $10.69B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.